Prostate cancer: Altering the natural history by dietary changes

National Medical Journal of India

Volumn 17, Issue 5, 2004, Pages 248-253

  Srivastava, Aseem R ^a   Dalela, D ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALPHA TOCOPHEROL; CALCITRIOL; DAIDZEIN; DIETHYLSTILBESTROL; DOCOSAHEXAENOIC ACID; GENISTEIN; ICOSAPENTAENOIC ACID; INDOMETACIN; ISOFLAVONE; LINSEED OIL; LYCOPENE; MYC PROTEIN; OLIVE OIL; OMEGA 6 FATTY ACID; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; POLYPHENOL; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P16; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; SABAL EXTRACT; SCATTER FACTOR RECEPTOR; SELENIUM; SOMATOMEDIN C; UNINDEXED DRUG; WARFARIN;

AGE; ANTIOXIDANT ACTIVITY; AWARENESS; CANCER MORTALITY; CANCER RESEARCH; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; CONTINUING EDUCATION; DIET THERAPY; DIETARY FIBER; DIETARY INTAKE; DISEASE COURSE; EVIDENCE BASED MEDICINE; FAMILY HISTORY; FAT INTAKE; GROWTH INHIBITION; HERBAL MEDICINE; HUMAN; INHIBITION KINETICS; LEGUME; LOW FAT DIET; MALE; MEDICAL LITERATURE; META ANALYSIS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATIENT CARE; PATIENT COUNSELING; PHYSICIAN ATTITUDE; PROSTATE CANCER; PROSTATECTOMY; RACE DIFFERENCE; RAT; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN CANCER; SOYBEAN; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VEGETABLE; WINE;

CAROTENOIDS; DIETARY FATS; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS; SELENIUM; SOY FOODS; VITAMIN D DEFICIENCY;

EID: 11344271129     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Wynder EL, Mabuchi K, Whitmore WF Jr. Epidemiology of cancer of the prostate. Cancer 1971;28:344-60.
2. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles county. Br J Cancer 1991; 63:963-6.
3. Uzzo RG, Bruner DW, Horwitz E. Prostate cancer prevention. Strategies and realities. In: Godec CJ (ed). Prostate cancer: Science and clinical practice. London: Academic Press; 2003:90-9.
4. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998; 58:204-9.
5. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW, et al. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 1995;154:414-21.
6. Chi SG, de Vere White RW, Muenzer JT, Gumerlock PH. Frequent alteration of CDKNZ (p 16 [INK4A] MTS1) expression in human primary prostate carcinomas. Clin Cancer Res 1997;3:1899-97.
7. Fleshner NE, Klotz LH. Diet, androgens, oxidative stress and prostate cancer susceptibility. Cancer Metastasis Rev 1998-99; 17:325-30.
8. Culig Z, Hobisch A, Cronauer MV, Hittmair A, Radmayr C, Bartsch G, et al. Activation of the androgen receptor by polypeptide growth factors and cellular regulators. World J Urol 1995;13:285-9.
9. Iwamura M, Sluss PM, Casamento JB, Cockett AT. Insulin-like growth factorI: Action and receptor characterization in human prostate cancer cell lines. Prostate 1993;22: 243-52.
10. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 1975;15:617-31.
11. Rose DP, Connolly JM. Dietary fat, fatty acids and prostate cancer. Lipids 1992;27: 798-803.
12. Statland BE. Nutrition and cancer. Clin Chem 1992;38 8B Pt 2):1587-94.
13. Giovannucci E, Rimm EB, Colditz GA, Stamfer MJ, Ascherio A, Chute CC, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 1993;85:1571-9.
14. Bairati I, Meyer F, Fradet Y, Moore L. Dietary fat and advanced prostate cancer. J Urol 1998;159:1271-5.
15. Ngo TH, Barnard RJ, Leung PS, Cohen P, Aronson WJ. Insulin-like growth factor 1 (IGF-1) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: Possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology 2003;144:2319-24.
16. Rose DP, Connolly JM. Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate 1991;18:243-54.
17. Norrish AE, Skeaff CM, Arribas GL, Sharpe SJ, Jackson RT. Prostate cancer risk and consumption of fish oils: A dietary biomarker-based case-control study. Br J Cancer 1999;81: 238-42.
18. Augustsson K, Michaud DS, Rimm EB, Leitzmann MF, Stampfer MJ, Willett WC, et al. A prospective study of intake of fish and marine fatty acids and prostate cancer. Cancer Epidemiol Biomarkers Prev 2003;12:64-7.
19. Leung G, Benzie IF, Cheung A, Tsao SW, Wong YC. No effect of a high-fat diet on promotion of sex hormone-induced prostate and mammary carcinogenesis in the Noble rat model. Br J Nutr 2002;88: 99-409.
20. Shike M, Latkany L, Riedel E, Fleisher M, Schatzkin A, Lanza E, et al. Lack of effect of a low-fat, high-fruit, -vegetable, and -fiber diet on serum prostate-specific antigen of men without prostate cancer: Results from a randomized trial. J Clin Oncol 2002; 20: 592-8.
21. Weisburger JH. Nutritional approach to cancer prevention with emphasis on vitamins, antioxidants, and carotenoids. Am J Clin Nutr 1991;53 (1 Suppl):226S-237S.
22. Zhou JR, Blackburn GL. Bridging animal and human studies: What are the missing segments in dietary fat and prostate cancer? Am J Clin Nutr 1997;66 (6 Suppl): 1572S-1580S.
23. Schwartz GG, Hulka. BS. Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis). Anticancer Res 1990;10 (5A):1307-11.
24. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992;70:2861-9.
25. Matsuoka LY, Wortsman J, Haddad JG, Kolm P, Hollis BW. Racial pigmentation and the cutaneous synthesis of vitamin D. Arch Dermatol 1991;127:536-8.
26. Konety BR, Schwartz GG, Acierno JS Jr, Becich MJ, Getzenberg RH. The role of vitamin D in normal prostate growth and differentiation. Cell Growth Differ 1996;7:1563-70.
27. Krill D, DeFlavia P, Dhir R, Luo J, Becich MJ, Lehman E, et al. Expression patterns of vitamin D receptor in human prostate. J Cell Biochem 2001;82:566-72.
28. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994; 54: 05-10.
29. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, et al. The human prostatic adenocarcinoma cell line LNCaP express biologically active, specific receptors for 1 alpha, 25-dihydroxyvitamin D3. Cancer Res 1992;52:515-20.
30. Blutt SE, Polek TC, Stewart LV, Kattan MW, Weigel NL. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res 2000;60: 779-82.
31. Gross C, Stamey T, Hancock S, Feldman D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 1998;159:2035-9; discussion 2039-40. Erratum in: J Urol 1998;160 (3 Pt 1):840.
32. Osborn JL, Schwartz GG, Smith DC, Bahnson R, Day R, Trump DL. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1995;1:195-8.
33. Stamey TA, McNeal JE. Adenocarcinoma of the prostate. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED Jr (eds). Campbell's Urology 6th ed. Philadelphia:WB Saunders, 1992:1159-1221.
34. Messina MJ, Persky V, Setchell KR, Barnes S. Soy intake and cancer risk: A review of the in vitro and in vivo data. Nutr Cancer 1994;21:113-31.
35. Geller J, Sionit L, Partido C, Li L, Tan X, Youngkin T, et al. Genistein inhibits the growth of human-patient BPH and prostate cancer in histoculture. Prostate 1998;34: 75-9.
36. Dalu A, Haskell JF, Coward L, Lamartiniere CA. Genistein, a component of soy, inhibits the expression of the EGF and ErbB2/Neu receptors in the rat dorsolateral prostate. Prostate 1998; 37: 6-43.
37. Pollard M, Luckert PH. Influence of isoflavones in soy protein isolates on development of induced prostate-related cancers in L-W rats. Nutr Cancer 1997;28:41-5.
38. Wang J, Eltoum IE, Lamartiniere CA. Dietary genistein suppresses chemically induced prostate cancer in Lobund-Wistar rats. Cancer Lett 2002;186:11-18.
39. Peterson TG, Barnes S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 1993;22: 35-45.
40. Hedlund TE, Johannes WU, Miller GJ. Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro. Prostate 2003;54:68-78.
41. Urban D, Irwin W, Kirk M, Markiewicz MA, Myers R, Smith M, et al. The effect of isolated soy protein on plasma biomarkers in elderly men with elevated serum prostate specific antigen. J Urol 2001;165:294-300.
42. Cohen LA, Zhao Z, Pittman B, Scimeca J. Effect of soy protein isolate and conjugated linoleic acid on the growth of Dunning R-3327-AT-1 rat prostate tumors. Prostate 2003;54:169-80.
43. Muth OH, Weswig PH, Whanger PD, Oldfield JE. Effect of feeding selenium-deficient ration to the subhuman primate (Saimiri sciureus). Am J Vet Res 1971;32:1603-5.
44. Young VR. Selenium: A case for its essentiality in man. N Engl J Med 1981;304: 1228-30.
45. Norppa H, Westermarck T, Laasonen M, Knuutila L, Knuutila S. Chromosomal effects of sodium selenite in vivo. I. Aberrations and sister chromatid exchanges in human lymphocytes. Hereditas 1980; 93:93-6.
46. Shamberger RJ, Corlett CL, Beaman KD, Kasten BL. Effect of selenium and other antioxidants on the mutagenicity of malonaldehyde. Fed Proc 1978;37:A265,261.
47. Jacobs MM, Matney TS, Griffin AC. Inhibitory effects of selenium on the mutagenicity of 2-acetylaminofluorene (AAF) and AAF derivatives. Cancer Lett 1977;2:319-22.
48. Griffin AC. Role of selenium in the chemoprevention of cancer. Adv Cancer Res 1979;29:419-42.
49. Daoud AH, Griffin AC. Effects of selenium and retinoic acid on the metabolism of N-acetylaminofluorene and N-hydroxyacetylamino-fluorene. Cancer Lett 1978;5: 231-7.
50. Marshall MV, Rasco MA, Griffin AC. Effects of selenium on benzo(a)pyrene metabolism. Fed Proc 1978;37:A628, 1383.
51. Combs GF Jr, Scott ML. Nutritional interrelationships of vitamin E and selenium. BioScience 1977;27:467-73.
52. Rotruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG. Selenium: Biochemical role as a component of glutathione peroxidase. Science 1973;179:588-90.
53. Chow CK. Nutritional influence on cellular antioxidant defense systems. Am J Clin Nutr 1979;32:1066-81.
54. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 029-35.
55. Milner JA. Effect of selenium on virally induced and transplantable tumor models. Fed Proc 1985;44:2568-72.
56. Thompson HJ, Wilson A, Lu J, Singh M, Jiang C, Upadhyaya P, et al. Comparison of the effects of an organic and an inorganic form of selenium on a mammary carcinoma cell line. Carcinogenesis 1994;15:183-6.
57. Ip C, el-Bayoumy K, Upadhyaya P, Ganther H, Vadhanavikit S, Thompson H. Comparative effect of inorganic and organic selenocyanate derivatives in mammary cancer chemoprevention. Carcinogenesis 1994;15:187-92.
58. Reddy BS, Rivenson A, Kulkarni N, Upadhyaya P, el-Bayoumy K. Chemoprevention of colon carcinogenesis by the synthetic organoselenium compound 1,4-phenylenebis (methylene) selenocyanate. Cancer Res 1992;52:5635-40.
59. Reddy BS, Rivenson A, el-Bayoumy K, Upadhyaya P, Pittman B, Rao CV. Chemoprevention of colon cancer by organoselenium compounds and impact of high-or low-fat diets. J Natl Cancer Inst 1997; 89: 06-12.
60. Shamberger RJ. Increase of peroxidation in carcinogenesis. J Natl Cancer Inst 1972;48:1491-7.
61. Shamberger RJ. Relationship of selenium to cancer. I. Inhibitory effect of selenium on carcinogenesis. J Natl Cancer Inst 1970;44:931-6.
62. Jacobs MM. Effects of selenium on chemical carcinogens. Prev Med 1980;9:362-7.
63. Schrauzer GN, Ishmael D. Effects of selenium and of arsenic on the genesis of spontaneous mammary tumors in inbred C3H mice. Ann Clin Lab Sci 1974;4:441-7.
64. Shamberger RJ, Tytko SA, Willis CE. Antioxidants and cancer. Part VI. Selenium and age-adjusted human cancer mortality. Arch Environ Health 1976;31:231-5.
65. Schrauzer GN, White DA, Schneider CJ. Cancer mortality correlation studies - III: Statistical associations with dietary selenium intakes. Bioinorg Chem 1977;7:23-31.
66. Salonen JT, Salonen R, Lappetelainen R, Maenpaa PH, Alfthan G, Puska P. Risk of cancer in relation to serum concentrations of selenium and vitamins A and E: Matched case-control analysis of prospective data. Br Med J (Clin Res Ed) 1985;290:417-20.
67. Willett WC, Polk BF, Morris JS, Stampfer Mi, Pressel S, Rosner B, et al. Prediagnostic serum selenium and risk of cancer. Lancet 1983;2:130-4.
68. Virtamo J, Valkeila E, Alfthan G, Punsar S, Huttunen JK, Karvonen MJ. Serum selenium and risk of cancer: A prospective follow-up of nine years. Cancer 1987;60: 145-8.
69. van den Brandt PA, Goldbohm RA, van't Veer P, Bode P, Dorant E, Hermus RJ, et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. J Natl Cancer Inst 1993;85:224-9.
70. Peleg I, Morris S, Hames CG. Is serum selenium a risk factor for cancer? Med Oncol Tumor Pharmacother 1985;2:157-63.
71. Broghamer WL, McConnell KP, Blotcky AL. Relationship between serum selenium levels and patients with carcinoma. Cancer 1976; 37:1384-8.
72. Shamberger RJ, Rukovena E, Longfield AK, Tytko SA, Deodhar S, Willis CE. Antioxidants and cancer. I. Selenium in the blood of normals and cancer patients. J Natl Cancer Inst 1973;50:863-70.
73. McConnell KP, Broghamer WL Jr, Blotcky AJ, Hurt OJ. Selenium levels in human blood and tissues in health and in disease. J Nutr 1975;105: 1026-31.
74. Calautti P, Moschini G, Stievano BM, Tomio L, Calzavara F, Perona G. Serum selenium levels in malignant lymphoproliferative diseases. Scand J Haematol 1980;24:63-6.
75. McConnell KP, Jager RM, Bland KI, Blotcky AJ. The relationship of dietary selenium and breast cancer. J Surg Oncol 1980;15:67-70.
76. Clark LC, Graham GF, Crounse RG, Grimson R, Hulka B, Shy CM. Plasma selenium and skin neoplasms: A case-control study. Nutr Cancer 1984;6:13-21.
77. Fex G, Pettersson B, Akesson B. Low plasma selenium as a risk factor for cancer death in middle-aged men. Nutr Cancer 1987; 10: 21-9.
78. Robinson MF, Godfrey PJ, Thomson CD, Rea HM, van Rij AM. Blood selenium and glutathione peroxidase activity in normal subjects and in surgical patients with and without cancer in New Zealand. Am J Clin Nutr 1979;32:1477-85.
79. Garland M, Morris JS, Stampfer MJ, Colditz GA, Spate VL, Baskett CK, et al. Prospective study of toenail selenium levels and cancer among women. J Natl Cancer Inst 1995;87:497-505.
80. Nomura A, Heilbrun LK, Morris JS, Stemmermann GN. Serum selenium and the risk of cancer, by specific sites: Case-control analysis of prospective data. J Natl Cancer Inst 1987;79:103-8.
81. Knekt P, Aromaa A, Maatela J, Alfthan G, Aaran RK, Teppo L, et al. Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. Int J Cancer 1988;42:846-50.
82. Ringstad J, Jacobsen BK, Tretli S, Thomassen Y. Serum selenium concentration associated with risk of cancer. J Clin Pathol 1988;41:454-7.
83. Coates RJ, Weiss NS, Daling JR, Morris JS, Labbe RF. Serum levels of selenium and retinol and the subsequent risk of cancer. Am J Epidemiol 1988;128:515-23.
84. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957-63. Erratum in: JAMA 1997; 277:1520.
85. Fan AM, Kizer KW. Selenium: Nutritional, toxicologic, and clinical aspects. West J Med 1990;153:160-7.
86. Hsing AW, Comstock GW, Abbey H, Polk BF. Serologic precursors of cancer: Retinol, carotenoids, and tocopherol and risk of prostate cancer. J Natl Cancer Inst 1990;82: 941-6.
87. Mills PK, Beeson WL, Phillips RL, Fraser GE. Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 1989;64:598-604.
88. Schuman LM, Mandel JS, Radke A, Seal U, Halberg F. Some selected features of the epidemiology of prostatic cancer: Minneapolis-St Paul, Minnesota case-control study, 1976-1979. In: Magnus K (ed). Trends in cancer incidence: Causes and practical implications. Washington, DC:Hemisphere Publishing; 1982:345-54.
89. Le Marchand L, Hankin JH, Kolonel LN, Wilken LR. Vegetable and fruit consumption in relation to prostate cancer risk in Hawaii: A reevaluation of the effect of dietary beta-carotene. Am J Epidemiol 1991;133:215-19.
90. Giovannucci E, Ascherio A, Rimm EB, Stamfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995;87:1767-76.
91. Stahl W, Sies H. Lycopene: A biologically important carotenoid for humans? Arch Biochem Biophys 1996;336:1-9.
92. Giovannucci E, Clinton SK. Tomatoes, lycopene, and prostate cancer. Proc Soc Exp Biol Med 1998;218:129-39.
93. Jain MG, Hislop GT, Howe GR, Ghadirian P. Plant foods, antioxidants, and prostate cancer risk: Findings from case-control studies in Canada. Nutr Cancer 1999;34: 173-84.
94. Key TJ, Silcocks PB, Davey GK, Appleby PN, Bishop DT. A case-control study of diet and prostate cancer. Br J Cancer 1997; 76:678-87.
95. Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, et al. Lower prostate cancer risk in men with elevated plasma lycopene levels; Results of a prospective analysis. Cancer Res 1999;59:1225-30.
96. Rao AV, Fleshner N, Agarwal S. Serum and tissue lycopene and biomarkers of oxidation in prostate cancer patients: A case-control study. Nutr Cancer 1999;33: 159-64.
97. Boileau TS, Clinton Z, Liao M, Monaca S, Donovan J, Erdman JW Jr. Lycopene, tomato powder and dietary restriction influence survival of rats with prostate cancer induced by NMU and testosterone. J Nutr 2001;131:191S.
98. Schulman CC, Ekane S, Zlotta AR. Nutrition and prostate cancer: Evidence or suspicion? Urology 2001;58:318-34.
99. Mucci LA, Tamimi R, Lagiou P, Trichopoulou A, Benetou V, Spanos E, et al. Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system? BJU Int 2001;87:814-20.
100. Kucuk O, Sakr W, Sarkar FH, Djuric Z, Pollak MN, Khachik F, et al. Lycopene supplementation in men with localized prostate cancer (PCa) modulates grade and volume of prostatic intraepithelial neoplasia (PIN) and tumor, level of serum PSA and biomarkers of cell growth, differentiation and apoptosis. Proc Annu Meet Am Assoc Cancer Res 1999;40:409.
101. Bowen P, Chen L, Stacewicz-Sapuntzakis M, Duncan C, Sharifi R, Ghosh L, et al. Tomato sauce supplementation and prostate cancer: Lycopene accumulation and modulation of biomarkers of carcinogenesis. Exp Biol Med (Maywood) 2002;227: 886-93.
102. Giovannucci E. A review of epidemiologic studies of tomatoes, lycopene, and prostate cancer. Exp Biol Med (Maywood) 2002; 227: 52-9.
103. Kristal AR, Cohen JH. Invited commentary: Tomatoes, lycopene, and prostate cancer. How strong is the evidence? Am J Epidemiol 2000;151:124-7.
104. Lin X, Gingrich JR, Bao W, Li J, Haroon ZA, Demark-Wahnefried W. Effect of flaxseed supplementation on prostatic carcinoma in transgenic mice. Urology 2002;60:919-24.
105. Romero I, Paez A, Ferruelo A, Lujan M, Berenguer A. Polyphenols in red wine inhibit the proliferation and induce apoptosis of LNCaP cells. BJU Int 2002;89: 950-4.
106. Moyad MA, Pienta KJ, Montie JE. Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease. Urology 1999;54:319-23; discussion 323-4.
107. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984;311:1281-6.
108. Citrin DL, Kies MS, Wallemark CB, Khandekar J, Kaplan E, Camacho F, et al. A phase II study of high-dose estrogens (diethylstilbestrol diphosphate) in prostate cancer. Cancer 1985; 56:457-60.
109. White J. PC-SPES - A lesson for future dietary supplement research. J Natl Cancer Inst 2002;94:1261-3.
110. Ansari MS, Gupta NP, Hemal AK. Chemoprevention of carcinoma prostate: A review. Int Urol Nephrol 2002;34:207-14.